annual CFO:
-$359.17M-$71.39M(-24.81%)Summary
- As of today (June 28, 2025), RXRX annual cash flow from operations is -$359.17 million, with the most recent change of -$71.39 million (-24.81%) on December 31, 2024.
- During the last 3 years, RXRX annual CFO has fallen by -$200.56 million (-126.45%).
- RXRX annual CFO is now -691.15% below its all-time high of -$45.40 million, reached on December 31, 2020.
Performance
RXRX Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
-$131.96M-$16.53M(-14.32%)Summary
- As of today (June 28, 2025), RXRX quarterly cash flow from operations is -$131.96 million, with the most recent change of -$16.53 million (-14.32%) on March 31, 2025.
- Over the past year, RXRX quarterly CFO has dropped by -$29.66 million (-28.99%).
- RXRX quarterly CFO is now -270.51% below its all-time high of $77.39 million, reached on March 31, 2022.
Performance
RXRX quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$388.83M-$29.66M(-8.26%)Summary
- As of today (June 28, 2025), RXRX TTM cash flow from operations is -$388.83 million, with the most recent change of -$29.66 million (-8.26%) on March 31, 2025.
- Over the past year, RXRX TTM CFO has dropped by -$72.07 million (-22.75%).
- RXRX TTM CFO is now -2082.36% below its all-time high of -$17.82 million, reached on March 31, 2020.
Performance
RXRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RXRX Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -24.8% | -29.0% | -22.8% |
| 3 y3 years | -126.5% | -270.5% | -670.4% |
| 5 y5 years | -529.7% | -640.6% | -2082.4% |
RXRX Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -330.0% | at low | -270.5% | at low | -670.4% | at low |
| 5 y | 5-year | -691.1% | at low | -270.5% | at low | -2082.4% | at low |
| alltime | all time | -691.1% | at low | -270.5% | at low | -2082.4% | at low |
RXRX Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$131.96M(+14.3%) | -$388.83M(+8.3%) |
| Dec 2024 | -$359.17M(+24.8%) | -$115.43M(+94.9%) | -$359.17M(+13.0%) |
| Sep 2024 | - | -$59.23M(-28.0%) | -$317.82M(-4.1%) |
| Jun 2024 | - | -$82.22M(-19.6%) | -$331.52M(+4.7%) |
| Mar 2024 | - | -$102.30M(+38.1%) | -$316.76M(+10.1%) |
| Dec 2023 | -$287.78M(+244.5%) | -$74.08M(+1.6%) | -$287.78M(+11.3%) |
| Sep 2023 | - | -$72.92M(+8.1%) | -$258.45M(+7.7%) |
| Jun 2023 | - | -$67.47M(-8.0%) | -$240.07M(+2.5%) |
| Mar 2023 | - | -$73.32M(+63.8%) | -$234.23M(+180.4%) |
| Dec 2022 | -$83.52M | -$44.75M(-18.0%) | -$83.52M(-16.4%) |
| Sep 2022 | - | -$54.54M(-11.5%) | -$99.93M(+27.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$61.62M(-179.6%) | -$78.44M(+55.4%) |
| Mar 2022 | - | $77.39M(-226.5%) | -$50.47M(-68.2%) |
| Dec 2021 | -$158.61M(+249.4%) | -$61.16M(+85.1%) | -$158.61M(+78.5%) |
| Sep 2021 | - | -$33.05M(-1.8%) | -$88.88M(+18.1%) |
| Jun 2021 | - | -$33.65M(+9.4%) | -$75.29M(+29.1%) |
| Mar 2021 | - | -$30.75M(-458.7%) | -$58.34M(+28.5%) |
| Dec 2020 | -$45.40M(-20.4%) | - | - |
| Dec 2020 | - | $8.57M(-144.1%) | -$45.40M(-15.9%) |
| Sep 2020 | - | -$19.46M(+16.5%) | -$53.97M(+56.4%) |
| Jun 2020 | - | -$16.70M(-6.3%) | -$34.52M(+93.7%) |
| Mar 2020 | - | -$17.82M | -$17.82M |
| Dec 2019 | -$57.04M | - | - |
FAQ
- What is Recursion Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual CFO year-on-year change?
- What is Recursion Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly CFO year-on-year change?
- What is Recursion Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals TTM CFO year-on-year change?
What is Recursion Pharmaceuticals annual cash flow from operations?
The current annual CFO of RXRX is -$359.17M
What is the all time high annual CFO for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual cash flow from operations is -$45.40M
What is Recursion Pharmaceuticals annual CFO year-on-year change?
Over the past year, RXRX annual cash flow from operations has changed by -$71.39M (-24.81%)
What is Recursion Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of RXRX is -$131.96M
What is the all time high quarterly CFO for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly cash flow from operations is $77.39M
What is Recursion Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, RXRX quarterly cash flow from operations has changed by -$29.66M (-28.99%)
What is Recursion Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of RXRX is -$388.83M
What is the all time high TTM CFO for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high TTM cash flow from operations is -$17.82M
What is Recursion Pharmaceuticals TTM CFO year-on-year change?
Over the past year, RXRX TTM cash flow from operations has changed by -$72.07M (-22.75%)